Mesa Air Group MESA 深 滬
已收盤 10-10 16:00:00 美东时间
1.41
+0.025
+1.81%
華盛通- 最 高1.4899
- 今 開1.40
- 成交量 28.16万股
- 最 低 1.3838
- 昨 收 1.385
- 總市值 5828.15万
- 52周最高 1.50
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.681
- 委 比 63.98%
- 總股本 4133.44万
- 歷史最高 17.40
- 量 比 1.71
- 振 幅 7.66%
- 歷史最低 0.40
- 每 手 1
- 風險率 0.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多The government shutdown's negative impact on the travel economy tops $1B
The U.S. Travel Association estimated that over $1.1 billion of travel spending has been lost since the beginning of the government shutdown. U.S. Travel Association CEO Geoff Freeman said the shutd...
10-09 02:22
Mesa Air Group Faces Nasdaq Compliance Deadline
Mesa Air Group ( ($MESA) ) has issued an update. On October 1, 2025, Mesa Air G...
10-04 04:42
MESA LABS DECLARES QUARTERLY DIVIDEND
Mesa Laboratories, Inc. (NASDAQ:MLAB) announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2025, to shareholders of record at the close of business on November 28, 2025. Mesa, a global leader in designing and manufacturing life science tools and critical quality control solutions, serves the pharmaceutical, healthcare, and medical device in...
10-03 15:01
Mesa Air Group Changes Fiscal Year-End To December 31 Starting In 2025
On September 24, 2025, the Board of Directors of Mesa Air Group, Inc. (the "Company") approved a change in the Company's fiscal year-end, moving from September 30 to December 31 of each year, effective for
09-29 19:35
Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
Mesoblast Limited, a global leader in allogeneic cellular medicines, reaffirms that its cell therapy products, including Ryoncil® (remestemcel-L), are manufactured in the U.S. and designated as U.S. origin products. Ryoncil® is the only FDA-approved allogeneic mesenchymal stromal cell therapy for treating steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients. The company ensures all products, including those for chro...
09-26 05:49
ASHFORD HOSPITALITY TRUST ANNOUNCES AGREEMENT TO SELL RESIDENCE INN SAN DIEGO SORRENTO MESA
DALLAS, Sept. 11, 2025 /PRNewswire/ -- Ashford Hospitality Trust, Inc. (NYSE: AHT) ("Ashford Trust" or the "Company") announced today that it has signed a definitive agreement to sell the 15...
09-12 04:25
Mesoblast Financial Results and Corporate Update Webcast
Mesoblast Limited, a global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast on August 28, 2025, to discuss its operational highlights and financial results for the year ended June 30, 2025. The webcast will begin at 6:30 PM EDT (8:30 AM AEST on August 29) and can be accessed via the provided link. The company specializes in developing off-the-shelf cell therapies targeting severe inflammatory conditions. Its...
08-27 11:00
Airline stocks outperform on Friday amid hopes for lower interest rates
Airline stocks gained on Friday after Federal Reserve Chairman Jerome Powell said conditions allow the FOMC to proceed carefully as it consider changes to the policy stance. "The baseline outlook and ...
08-23 01:57
Sun Country Airlines Names D. Torque Zubeck As Senior Vice President And Chief Financial Officer, Effective September 2
Sun Country Airlines (NASDAQ:SNCY) announced today that D. Torque Zubeck, formerly a managing director with Alaska Airlines, will join Sun Country as Senior Vice President and Chief Financial Officer on Tuesday,
08-13 23:51
Mesa Labs Announces First Quarter Results
Mesa Laboratories reported first quarter FY26 results with total revenues of $59.5 million, up 2.4% from FY25, though core organic growth was 0.4%. Operating income fell 45.1% to $3.1 million, impacted by FX and stock-based compensation. The SDC division grew 7.5% organically, while CG revenues declined 10.7% due to China contraction.
08-05 12:00
